A panel of international experts in the field of diabetes and diabetes technology met in Oslo, Norway, for the 11th Annual Symposium on Self-Monitoring of Blood Glucose. The goal of these meetings is to share current knowledge, facilitate new collaborations, and encourage further research projects that can improve the lives of people with diabetes. The 2018 meeting comprised a comprehensive scientific program and four keynote lectures.
Get full access to this article
View all access options for this article.
References
1.
DanneT, NimriR, BattelinoT, et al.: International consensus on use of continuous glucose monitoring. Diabetes Care, 2017; 40:1631–1640.
2.
KovatchevBP, PatekSD, OrtizEA, BretonMD: Assessing sensor accuracy for non-adjunct use of continuous glucose monitoring. Diabetes Technol Ther, 2015; 17:177–186.
3.
MarsoSP, McGuireDK, ZinmanB, et al.: Efficacy and safety of degludec versus glargine in type 2 diabetes. Engl J Med, 2017; 24;377:723–732.
4.
GargSK, HenryRR, BanksP, et al.: Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med, 2017; 377:2237–2348.
5.
DandonaP, MathieuC, PhillipM, et al.: Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol, 2017; 5:864–876.
6.
ColagiuriS, LeeCM, WongTY, et al.: Glycemic thresholds for diabetes-specific retinopathy. Diabetes Care, 2011; 34:145–150.
7.
CoutinhoM, GersteinHC, WangY, YusufS: The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care, 1999; 22:233–240.
8.
ShawJE, ZimmetPZ, de CourtenM, et al.: Impaired fasting glucose or impaired glucose tolerance. What best predicts future diabetes in Mauritius?. Diabetes Care, 1999; 22:399–402.
9.
ZhangX, GreggEW, WilliamsonDF, et al.: A1C level and future risk of diabetes: a systematic review. Diabetes Care, 2010; 33:1665–1673.
10.
TuomilehtoJ, LindströmJ, ErikssonJG, et al.: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med, 2001; 344:1343.
11.
Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med, 2002; 346:393–403.
12.
Diabetes Prevention Program Research Group: Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol, 2015; 3:866–875.
13.
GersteinHC, BoschJ, DagenaisGR, et al.: Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med, 2012; 367:319–328.
14.
Pi-SunyerX, AstrupA, FujiokaK, et al.: A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med, 2015; 373:11–22.
15.
GædeP, Lund-AndersenH, ParvingH-H, PedersenO: Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med, 2008; 358:580–591.
16.
PontzerH, RaichlenDA, WoodBM, et al.: Hunter-gatherer energetics and human obesity. PLoS One, 2012; 7:e40503.
17.
PhillipM, BattelinoT, AtlasE, et al.: Nocturnal glucose control with an artificial pancreas at a diabetes camp. N Engl J Med, 2013; 368; 824–833.
18.
ThabitH, TauschmannM, AllenJM, et al.: Home use of an artificial beta cell in type 1 diabetes. N Engl J Med, 2015; 373; 21291–2140.
19.
GargSK, WeinzimerSA, TamborlaneWV, et al.: Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes. Diabetes Technol Ther, 2017; 19:155–163.
20.
DassauE, PinskerJE, KudvaYC et al.: 12-Week 24/7 ambulatory artificial pancreas with weekly adaptation of insulin delivery settings: effect on hemoglobin A1c and hypoglycemia. Diabetes Care, 2017; 40:1719–1726.
21.
DassauE, RenardE, PlaceJ, et al.: Intraperitoneal insulin delivery provides superior glycaemic regulation to subcutaneous insulin delivery in model predictive control-based fully-automated artificial pancreas in patients with type 1 diabetes: a pilot study. Diabetes Obes Metab, 2017; 19:1698–1705.
22.
RiddellMC, GallenIW, SmartCE, et al.: Exercise management in type 1 diabetes: a consensus statement. Lancet Diabetes Endocrinol, 2017; 5:377–390.
23.
PivovarovJA, TaplinCE, RiddellMC: Current perspectives on physical activity and exercise for youth with diabetes. Pediatr Diabetes, 2015; 16:242–255.
24.
HeiseT, PieberTR, DanneT, et al.: A pooled analysis of clinical pharmacology trials investigating the pharmacokinetic and pharmacodynamic characteristics of fast-acting insulin aspart in adults with type 1 diabetes. Clin Pharmacokinet, 2017; 56:551–559.
25.
MathieuC, BodeBW, FranekE, et al.: Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): a 52-week, randomized, treat-to-target, phase III trial. Diabetes Obes Metab, 2018; 20:1148–1155.
26.
BoweringK, CaseC, HarveyJ, et al.: Faster aspart versus insulin aspart as part of a basal-bolus regimen in inadequately controlled type 2 diabetes: the onset 2 trial. Diabetes Care, 2017; 40:951–957.
27.
ParkinCG, SchwenkeS, OssegeAK, GruchmannT: Use of an integrated tool for interpretation of blood glucose data improves correctness of glycemic risk assessment in individuals with type 1 and type 2 diabetes. J Diabetes Sci Technol, 2017; 11:74–82.
28.
KropffJ, ChoudharyP, NeupaneS, et al.: Accuracy and longevity of an implantable continuous glucose sensor in the PRECISE Study: a 180-day, prospective, multicenter, pivotal trial. Diabetes Care, 2017; 40:63–68.
29.
ChristiansenM, KlaffLJ, BrazgR, et al.: A prospective, multicenter evaluation of the accuracy of a novel implanted continuous glucose sensor: PRECISE II. Diabetes Technol Ther, 2018:20:197–206.
30.
AgiostratidouG, AnhaltH, BallD, et al.: Standardizing clinically meaningful outcome measures beyond HbA1c for type 1 diabetes: a consensus report of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the Endocrine Society, JDRF International, The Leona M. and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D Exchange. Diabetes Care, 2017; 40:1622–1630.
31.
PetrieJR, PetersAL, BergenstalRM, et al.: Improving the clinical value and utility of CGM systems: issues and recommendations: a joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group. Diabetes Care, 2017; 40:1614–1621.
32.
BergenstalRM, AhmannAJ, BaileyT, et al.: Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the Ambulatory Glucose Profile (AGP). Diabetes Technol Ther, 2013; 15:198–211.
33.
KosiborodM, CavenderMA, FuAZ, et al.: Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL Study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors). Circulation, 2017; 136:249–259.
34.
BirkelandKI, JørgensenME, CarstensenB, et al.Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Lancet Diabetes Endocrinol, 2017; 5:709–717.
35.
PerssonF, NyströmT, JørgensenME, et al.: Dapagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in people with type 2 diabetes (CVD‐REAL Nordic) when compared with dipeptidyl peptidase‐4 inhibitor therapy: a multinational observational study. Diabetes Obes Metab, 2018; 20:344–351.
36.
ZeeviD, KoremT, ZmoraN, et al.: Personalized nutrition by prediction of glycemic responses. Cell, 2015; 163:1079–1094.
37.
KoremT, ZeeviD, ZmoraN, et al.: Bread affects clinical parameters and induces gut microbiome-associated personal glycemic responses. Cell Metab, 2017; 25:1243–1254.
38.
LindströmJ, Ilanne-ParikkaP, PeltonenM, et al.: Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet, 2006; 368:1673–1679.
39.
LiG, ZhangP, WangJ, et al.: The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet, 2008; 371:1783–1789.
40.
ElyEK, GrussSM, LumanET, et al.: A national effort to prevent type 2 diabetes: participant-level evaluation of CDC's National Diabetes Prevention Program. Diabetes Care, 2017:40:1331–1341.
41.
DunkleyAJ, BodicoatDH, GreavesCJ, et al.: Diabetes prevention in the real world: effectiveness of pragmatic lifestyle interventions for the prevention of type 2 diabetes and of the impact of adherence to guideline recommendations. Diabetes Care, 2014; 37:922–933.
42.
KoivistoJ, HamariJ: The rise of motivational information systems: a review of gamification research. 2018 (working paper). https://people.uta.fi/∼kljuham/Manuscript-5.pdf (accessed July12, 2018).
43.
HamariJ, HassanL, DiasA: Gamification, quantified-self or social networking? Matching users' goals with motivational technology. User Model User-Adapt Interact, 2018; 28:35–74.
44.
EkelundU, Steene-JohannessenJ, BrownWJ, et al.: Does physical activity attenuate, or even eliminate, the detrimental association of sitting time with mortality? A harmonised meta-analysis of data from more than 1 million men and women. Lancet, 2016; 388:1302–1310.
45.
BalducciS, ZanusoS, NicolucciA, et al.: Effect of an intensive exercise intervention strategy on modifiable cardiovascular risk factors in subjects with type 2 diabetes mellitus: a randomized controlled trial: the Italian Diabetes and Exercise Study (IDES). Arch Intern Med, 2010; 170:1794–1803.
46.
BalducciS, SacchettiM, HaxhiJ, et al.: The Italian Diabetes and Exercise Study 2 (IDES-2): a long-term behavioral intervention for adoption and maintenance of a physically active lifestyle. Trials, 2015; 16:569.
47.
OECD (2014), OECD Reviews of Health Care Quality: Italy 2014: Raising StandardsOE, CDPublishing. http://dx.doi.org/10.1787/9789264225428-en (accessed July20, 2018).
48.
RossiMCE, LucisanoG, ComaschiM, et al.: Quality of diabetes care predicts the development of cardiovascular events: results of the AMD-QUASAR study. Diabetes Care, 2011; 34:347–352.
49.
CarlsG, HuynhJ, TuttleE, et al.: Achievement of glycated hemoglobin goals in the US remains unchanged through 2014. Diabetes Ther, 2017; 8:863–873.
50.
MillerKM, FosterNC, BeckRW, et al.; T1D exchange clinic network. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D exchange clinic registry. Diabetes Care, 2015; 38:971–978.
51.
KulzerB, DaenschelW, DaenschelI, et al.: Integrated personalized diabetes management improves glycemic control in patients with insulin-treated type 2 diabetes: results of the PDM-ProValue study program. Diabetes Res Clin Pract, 2018; pii: S0168-8227(18)31156-2.
52.
HompeschM, KalcherK, DebongF, MorrowL: Significant improvement of blood glucose control in a high risk population of type 1 diabetes using a mobile health app—a retrospective observational study. Diabetes Technol Ther, 2017; 64(Suppl 1):2337.
53.
HompeschM, HergesheimerL, KalcherK, et al.: Retrospective analysis of impact on SMBG and glycemic control of mobile health (mHealth)-application for diabetes management. J Diabetes Sci Tech, 2017; 11; 346–437.
54.
HompeschM, KalcherK, DebongF: High-risk population using mobile logging application shows significant reduction in LBGI. Diabetes, 2017; 66(Suppl 1):952-P.
55.
KhattabM, KhaderYS, Al-KhawaldehA, AjlouniK: Factors associated with poor glycemic control among patients with type 2 diabetes. J Diabetes Complications, 2010; 2484–89.
56.
BoyleJP, ThompsonTJ, GreggEW, et al.: Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr, 2010; 8:29.
57.
KankeuHT, SaksenaP, XuK, EvansDB: The financial burden from non-communicable diseases in low-and middle-income countries: a literature review. Health Res Policy Syst, 2013; 11:31.
58.
OmarAS: Time in range: a fourth domain in glycemic control or a glucose variability alternative?. Mayo Clin Proc, 2016; 91:1147.
59.
World Economic Forum (WEF): Value in Healthcare—laying the foundation for healthy systems transformation. 2017. http://www3.weforum.org/docs/WEF_Insight_Report_Value_Healthcare_Laying_Foundation.pdf (accessed July15, 2018)
